Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment
International Journal of Tuberculosis and Lung Disease, Volume 18, No. 8, Year 2014
Notification
URL copied to clipboard!
Description
SETTING: St Peter's TB Specialized Hospital, Addis Ababa, Ethiopia. OBJECTIVE: To estimate the prevalence of mutations that cause resistance to isoniazid (INH) and rifampicin (RMP) and assess the effects of these mutations on second-line anti-tuberculosis treatment. DESIGN: GenoType®MTBDRplus assay results and clinical data documented at St Peter's TB Specialized Hospital over 3 years were retrospectively collected and analysed. RESULTS: The results indicated that 68.7% (n = 470) of RMP-resistant isolates had mutations at codon 531 (S531L) of the rpoB gene, while 93% (n = 481) of the INH-resistant isolates had mutations at codon 315 (S315T1) of the katG gene. The proportion of inhA mutations was 0.8% (n = 481). Treatment outcome was unfavourable in 23.7% (n = 76) of patients treated with second-line anti-tuberculosis drugs. Mutations in other codons of the rpoB gene (P > 0.05) and in the inhA promoter region (P > 0.05) were not associated with unfavourable treatment outcomes. CONCLUSION: The predominant mutations in RMP and INH resistance were observed at codons 531 and 315 in the rpoB and katG genes, respectively. Mutations in the inhA region were rare, which shows its minimal contribution to the development of resistance to ethionamide. This also suggests that treating multi-drug-resistant TB patients with high doses of INH may have little effect. © 2014 The Union.
Authors & Co-Authors
Abate, Dereje
Ethiopia, Addis Ababa
Addis Ababa University
Ethiopia, Addis Ababa
St Peter tb Specialised Hospital
Tedla, Yared
Ethiopia, Addis Ababa
St Peter tb Specialised Hospital
Meressa, Daniel
Ethiopia, Addis Ababa
St Peter tb Specialised Hospital
Ethiopia, Addis Ababa
Global Health Committee
Ameni, G.
Ethiopia, Addis Ababa
Addis Ababa University
Statistics
Citations: 32
Authors: 4
Affiliations: 3
Identifiers
Doi:
10.5588/ijtld.13.0926
ISSN:
10273719
Research Areas
Genetics And Genomics
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Ethiopia